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Abstract
Recently, some types of MnO nanoparticle (Mn-NP) with favorable imaging capacity have
been developed to improve the biocompatible profile of the existing Mn-based MRI contrast
agent Mn-DPDP; however, the overall bio-effects and potential toxicity remain largely
unknown. In this study, 1H NMR-based metabolic profiling, integrated with traditional
biochemical analysis and histopathological examinations, was used to investigate the
absorption, distribution, metabolism, excretion and toxicity of Mn-NPs as candidates for MRI
contrast agent. The metabolic responses in biofluids (plasma and urine) and tissues (liver,
spleen, kidney, lung and brain) from rats could be divided into four classes following Mn-NP
administration: Mn biodistribution-dependent, time-dependent, dose-dependent and
complicated metabolic variations. The variations of these metabolites involved in lipid, energy,
amino acid and other nutrient metabolism, which disclosed the metabolic fate and biological
effects of Mn-NPs in rats. The changes of metabolic profile implied that the disturbance and
impairment of biological functions induced by Mn-NP exposure were correlated with the
particle size and the surface chemistry of nanoparticles. Integration of metabonomic
technology with traditional methods provides a promising tool to understand the toxicological
behavior of biomedical nanomaterials and will result in informed decision-making during drug
development.
S Online supplementary data available from stacks.iop.org/Nano/24/455102/mmedia
(Some figures may appear in colour only in the online journal)
1. Introduction
Manganese (Mn) is one of the more abundant elements in the
biosphere. The unique electronic configuration of the 3d5 shell
of Mn2+ makes it an excellent magnetic probe for applications
in the biomedical field such as drug delivery and biomedical
imaging as an MRI contrast agent [1, 2]. At present, there is
one commercial Mn-based MRI contrast agent, mangafodipir
trisodium (Mn-DPDP), in clinical use. However, Mn-based
complexes are easy to dissociate after administration to
yield free Mn2+ because of the conversion between the
six- and seven-coordinated states, which accounts for the
in vivo instability of the Mn-DPDP chelate compared with
gadolinium-based contrast agents [3]. Due to its physiological
role, exposure to excess Mn can induce deleterious effects
on the central nervous system and cause parkinsonism-like
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syndrome, especially in patients with liver failure [4]. The
in vivo instability of Mn-DPDP has raised especial concerns
about its potential toxicity from the Mn2+ ions, which led
to its gradual withdrawing from the market. It also suggests
that it is necessary to find biocompatible and thermodynamic
stable Mn compounds.
With the tremendous advances in nanotechnology, some
types of Mn-NPs-based MRI contrast agent with well defined
morphology and high solubility have been developed [5–7].
They exhibit favorable behaviors in detection, localization,
characterization and evaluation of hepatic lesions and provide
clinical advantages over the existing Mn-based MRI contrast
agent, Mn-DPDP. Some of them have offered an improved
biocompatible profile; however, the overall and systematic
research on Mn-based nano-contrast agents is still at a
relatively early stage.
Nowadays, the strategy of utilizing ADME/Tox tools
for lead optimization and clinical candidate selection is the
cornerstone of modern drug discovery. The traditional in vivo
ADME/Tox studies that rely on the use of radiotracer may
be still invaluable for drug standardization and assessment;
however, the advances in ‘omic’ technologies present
their challenges and advantages in drug development [8].
Metabonomics, as one of the omics, is a systematic approach
for studying the dynamic metabolic response of a living
system to pathophysiological stimuli, which highlights the
biological variations at metabolite level and more closely
mirrors the phenotype of the living system by stoichiometric
analysis [9]. Thus, investigation of in vivo metabolic changes
induced by nanoparticles may provide a detailed description
of the corresponding bio-responses; further, it would help to
disclose the structure–activity relationship and to elucidate
the fate of nanoparticles, i.e. their distribution, degradation,
metabolism and excretion [10].
In this study, we integrated 1H NMR-based metabo-
nomic strategy with the conventional biochemical methods,
including blood biochemical analysis, ICP-AES determina-
tion of Mn concentration in tissues and histopathological
examination, to evaluate the acute bio-related response in rats
to an intravenous injection of Mn-NPs and investigate their
biodistribution and metabolic fate.
2. Materials and methods
2.1. Synthesis and characterization of MnO nanoparticles
Size-homogeneous and monodisperse 10 nm MnO nanopar-
ticles were synthesized by high-temperature thermal decom-
position of manganese oleate complex as reported in the
previous literature [11]. Mn-NPs dried on copper grids were
visualized by transmission electron microscopy (TEM) (see
figure S1 in the supplementary material available at stacks.
iop.org/Nano/24/455102/mmedia). Mn-NPs were freshly well
dispersed by ultrasound in saline solution before use.
Prior to animal experiments, the Mn concentration of the
nanoparticles in phosphate buffer solution was determined
by inductively coupled plasma–atomic emission spectrometry
(ICP-AES).
2.2. Animal handling and sample collection
All animal experimental protocols complied with the local
guidelines for animal use and care, and all animal studies
were performed at specific pathogen free (SPF) facility of
Xiamen University Laboratory Animal Center (XMULAC).
A total of 43 nine-week-old male SD rats (243 ± 13 g)
were used in our study. The environment conditions were set
at 21–26 ◦C with a relative humidity of 50 ± 10%, and a
12/12 h light/dark cycle. Food and tap water were provided
ad libitum, and body weights were recorded daily. After one
week of acclimatization, a single dose of Mn-NPs in saline
was administrated intravenously to the rats at two dose levels
of 10 mg Mn per kg body weight (bw) (n = 15) and 40 mg Mn
per kg bw (n = 15). A control group (n = 13) was treated
with saline only. Individual urine samples were collected
in ice-cooled vessels containing 1% sodium azide (0.1 ml)
for 2 h using a metabolic cage at time points 0, 6, 24 and
48 h post-dose (pd), respectively, and immediately frozen at
−80 ◦C. Animals were sacrificed by exsanguination under
isoflurane anesthesia at time points 6 (six rats in each group)
and 48 h (remaining rats) pd. The blood sample was divided
into two aliquots, one serum for biochemical analysis and the
other heparinized plasma for NMR spectroscopic analysis.
After weighing, brain, kidney, liver, lung and spleen tissue
were excised in triplicate: one being fixed in 10% formalin
for histopathological examination, the other two immediately
snap-frozen in liquid nitrogen for tissue extraction and for
ICP-AES analysis. These samples were stored at−80 ◦C until
used.
2.3. Histopathology
The randomly selected samples of kidney, liver, lung and
spleen tissue from Mn-NP-treated and control rats were
fixed in 10% formalin. After dehydrating, the biopsies
embedded in wax were sectioned at 5 µm, and stained with
hematoxylin and eosin for histopathological examination by
light microscopy.
2.4. Blood biochemical analysis
Clinical chemistry analysis of serum was carried out by
standard spectrophotometric methods on a Roche Modular
P800 automatic analyzer (Roche Diagnostics, Germany). The
biochemical parameters included glucose, indirect bilirubin,
total bile acid, UA, BUN, creatinine (Cn), BUN/Cn ratio,
enzymes (ALT, AST, GGT, ALP, LDH and AST/ALT ratio),
protein metabolism (total protein, albumin, globulin and
Alb/Glo ratio) and lipid metabolism (TG, total cholesterol,
HDL-C and LDL-C). All parameters are expressed as mean±
standard deviation (SD).
2.5. Sample preparation and 1H NMR spectroscopic analysis
Samples of plasma (255 µl) were mixed with 255 µl
of deuterated phosphate buffer solution (NaH2PO4 and
K2HPO4, 60 mM, pH 7.4). After centrifugation at 10 000 g
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at 4 ◦C for 10 min to remove the precipitates, 500 µl of the
supernatants was transferred into a 5 mm NMR tube and
analyzed by NMR spectroscopy. 1H NMR spectra of these
samples were acquired using a 500 MHz Varian spectrometer
at 296 K. Standard 1D 1H spectra were acquired with a
water-suppressed CPMG pulse sequence. For each sample,
64 FIDs were collected into 20 K data points over a spectral
width of 10 000 Hz with a relaxation delay of 0.23 ms.
Samples of urine (455 µl) were mixed with 55 µl
of deuterated phosphate buffer solution (NaH2PO4 and
K2HPO4, 1.5 M, including 0.1% TSP (sodium 3-
(trimethylsilyl) propionate-2,2,3,3-d4), pH 7.4) to minimize
any gross variation in the pH of the urine samples. The
mixture was left to stand for 10 min and centrifuged at
10 000 g at 4 ◦C for 10 min to remove the precipitates. 500 µl
of the supernatants were transferred into a 5 mm NMR tube
and analyzed by NMR spectroscopy. 1H NMR spectra of
these samples were acquired using the standard NOESYPR1D
pulse sequence on a 500 MHz Varian spectrometer at 296 K.
For each sample, 128 FIDs were collected into 40 K data
points over a spectral width of 10 000 Hz with a relaxation
delay of 0.23 ms.
The polar metabolites in the rat tissue were extracted
according to the protocol established by Wu et al [12]. In
brief, pre-weighed brain, kidney, liver, lung, or spleen samples
(100 mg per sample) were homogenized in 400 µl of CH3OH
and 85 µl of H2O at 4 ◦C. The homogenates were transferred
into a 2.5 ml tube, and combined with 400 µl of CHCl3 and
200 µl of H2O and then kept in vortex for 60 s. After 10 min
partitioning on ice, the samples were centrifuged for 5 min
(10 000 g, 4 ◦C). The upper supernatants were transferred into
1.5 ml tubes, and lyophilized to remove CH3OH and H2O.
The extracts were reconstituted in 0.5 ml D2O containing
1 mM TSP, then transferred into 5 mm NMR tubes and
analyzed by NMR spectroscopy. 1H NMR spectra of these
samples were acquired on a Bruker-AV600 spectrometer at
296 K. Standard 1D 1H spectra were acquired with a ‘ZGPR’
pulse sequence. For each sample, 64 free induction decays
(FIDs) were collected into 64 k data points over a spectral
width of 12 000 Hz with a relaxation delay of 6.5 µs and an
acquisition time of 2.66 s.
2.6. Spectral processing and pattern recognition
The FIDs were multiplied by an exponential function
corresponding to a 1 Hz line-broadening factor before Fourier
transformation. The acquired NMR spectra were manually
phased and baseline-corrected using Bruker TOPSPIN 3.0
and referenced to the CH3 resonance of lactate at δ 1.33 for
plasma spectra and TSP at δ 0.00 for urine and tissue extract
samples. The peaks observed were assigned on the basis of
their chemical shifts and signal multiplicity [13].
Each 1H NMR spectrum of plasma, urine, or aqueous
tissue extract was segmented into regions of 0.005 ppm using
AMIX (v.3.8, Bruker Biospin). The segments of δ 6.0–5.5
and δ 5.20–4.29 in the plasma spectra (δ 9.0–0.5), and of
δ 6.02–5.45 and δ 5.35–4.24 in the urine spectra (δ 9.5–0.5)
were removed to exclude the urea signal and the uncertainty of
residual water signal. In the case of the chloroform/methanol
tissue extract, the regions of δ 5.226–4.675 and δ 3.40–3.31
in the spectra were excluded to remove variation in residual
water and methanol signal.
Normalization was applied to the total sum of integrated
data from each sample, which makes the data directly
comparable with each other. The mean centered data were
analyzed by principal component analysis (PCA) to reveal
trends, highlight outliers, and show clusters among the
observations in SIMCA-P+ 11.0 (Umetrics, Sweden). Then,
the orthogonal projection to latent structure with discriminant
analysis (OPLS-DA) method was utilized to identify the
differential metabolites responsible for Mn-NP exposure on
unit variance scaled data. Score plots provide the most
efficient 2D representation of the information contained in the
data set, and the corresponding coefficient loading plots were
used to describe the influence of the variables on the scores.
Here, a correlation coefficient (determined by the Pearson’s
product-moment correlation coefficient) of |r| > 0.755 (the
degree of freedom is equal to 5) was used as the cut-off value
that gave a statistically significant result at the level P < 0.05.
2.7. Statistical analysis
The data were expressed as mean± SD. Inter-group variations
were assessed by one-way analysis of variance (ANOVA)
followed by a post hoc Fisher least significant difference test.
The criterion for statistical significance was p < 0.05.
3. Results and discussion
3.1. Effect of Mn-NPs on gross histological morphology
Microscopic examinations were conducted on the selected
tissues from low-dose (10 mg Mn kg−1), high-dose
(40 mg Mn kg−1), and control rats. No apparent pathological
change was observed in the kidney after administration
compared with the controls (figure S2 in the supplemen-
tary material available at stacks.iop.org/Nano/24/455102/
mmedia). The portal area of the liver and hepatocytes around
the central vein showed normal results, except a moderate
increase in the white blood cell count displayed around the
bile ducts at 48 h after high-dose Mn-NP administration
(denoted by an arrow in figure 1(B)). No obvious histological
change in the lung was observed in any treatment group
compared with the controls, although there was a relative
lymphocytosis in the lung interstitium of the high-dose
group at 48 h after treatment (figure 1(D)). No apparent
histological change was observed in the spleen in either the
low- or high-dose group at 6 h after administration (data not
shown); however, at 48 h after administration the spleen was
characterized as a mild enlarged area of white pulp with red
pulp normal (denoted by arrow in figure 1(F)).
3.2. The ratios of tissue to body weights
Figure 2 shows the ratios of the tissues to body wet-weight.
The only change in the L48 group came from the ratio
3
Nanotechnology 24 (2013) 455102 J Li et al
Figure 1. Photomicrographs of representative sections of the liver ((A) and (B)), lung ((C) and (D)), and spleen ((E) and (F)) from control
((A), (C) and (E)) and high-dose ((B), (D) and (F)) Mn-NP-treated rats at 48 h pd. The tissue sections were stained with hematoxylin–eosin
and observed under a 100× microscope. The arrows in (B) and (D) show the increased inflammatory cells in the liver and the lung,
respectively, and the arrow in (F) shows the mild enlarged area of white pulp in the spleen.
Figure 2. Effect of MnO nanoparticle administration on
tissue/body weight ratio (%). C, control group; L, low-dose group;
H, high-dose group; 6, 6 h post-dose; 48, 48 h post-dose.
∗ Significant differences between two groups as judged by Student’s
t-test (∗P < 0.05; ∗∗P < 0.001).
of spleen/BD, which increased to 114% of control (P <
0.05), while the ratios of kidney/BD, liver/BD, lung/BD,
and spleen/BD in the H48 group showed increases to 108%
(P < 0.001), 119% (P < 0.001), 122% (P < 0.05), and 131%
(P < 0.05) of control, respectively. We assume that both
Mn-NP-induced body weight loss and tissue weight gain
due to inflammation contributed to this rise of the ratios, as
observed in microscopic examination (figure 1).
3.3. Biodistribution of Mn in the different tissues
The distribution of Mn-NPs in tissues was evaluated
by ICP-AES (figure 3). Most of the nanoparticles were
transferred into liver and spleen following the low-dose
Mn-NP administration. By contrast, high-dose Mn-NPs
induced a more widespread tissue distribution. Mn-NP
contents in liver, lung, and spleen demonstrated a similar
deposited order: H6 > L6 > H48 > L48 within their
respective groups; however, a different deposited order, H6
> H48 > L6 > L48, was displayed in the brain and
kidney. These results demonstrate a varied biodistribution and
excretion in the different tissues. Furthermore, according to
the data, the overall clearance rate of Mn-NPs from lung and
spleen was faster than that from kidney and liver, while it
was the slowest to clearance from the brain. Such observation
4
Nanotechnology 24 (2013) 455102 J Li et al
Table 1. Effect of MnO nanoparticle administration on blood biochemical indices.
Indices C6a L6 H6 C48 L48 H48
TP (g/L)b 43.65 ±7.36c 54.10 ± 2.10d 47.33 ± 3.37 56.63 ± 2.88 58.47 ± 2.36 54.58 ± 3.21
Alb (g/L) 25.20 ± 3.43 30.08 ± 0.62d 27.47 ± 1.38 31.36 ± 0.95 29.04 ± 0.68e 26.76 ± 1.54e
Glo (g/L) 18.45 ± 4.15 24.02 ± 1.61d 19.87 ± 2.10 25.27 ± 1.97 29.42 ± 1.77e 27.82 ± 1.98d
Alb/Glo 1.39 ± 0.17 1.26 ± 0.07 1.39 ± 0.10 1.25 ± 0.06 0.99 ± 0.04e 0.96 ± 0.05e
Ibil (µmol/L) 1.00 ± 0.39 1.47 ± 0.14d 1.62 ± 0.23d 1.66 ± 0.20 1.48 ± 0.10d 1.72 ± 0.23
ALT (U/L) 34.40 ± 8.44 64.67 ± 8.16e 122.40 ± 27.68e 42.50 ± 2.07 50.22 ± 6.85d 43.33 ± 7.31
AST (U/L) 145.20 ± 38.15 265.50 ± 18.36e 623.17 ± 107.85e 178.00 ± 18.69 164.33 ± 28.43 137.22 ± 25.60e
AST/ALT 3.57 ± 1.06 4.15 ± 0.46 4.65 ± 0.98 4.07 ± 0.49 3.31 ± 0.69d 3.20 ± 0.53d
GGT (U/L) 0.08 ± 0.04 2.00 ± 0.00e 3.67 ± 1.75d 0.10 ± 0.00 0.80 ± 0.40e 4.38 ± 2.33e
ALP (U/L) 211.20 ± 37.93 321.67 ± 38.54e 295.83 ± 26.70d 309.00 ± 58.58 322.89 ± 74.70 363.38 ± 52.37
TG (mmol/L) 0.76 ± 0.16 1.84 ± 0.37e 1.99 ± 0.73d 0.99 ± 0.27 0.59 ± 0.11d 0.82 ± 0.29
TC (mmol/L) 1.86 ± 0.34 2.57 ± 0.35e 2.32 ± 0.19d 2.32 ± 0.14 2.74 ± 0.20e 3.00 ± 0.34e
HDL-C
(mmol/L)
0.51 ± 0.09 0.71 ± 0.06e 0.58 ± 0.05 0.68 ± 0.07 0.81 ± 0.06e 0.71 ± 0.14
LDL-C
(mmol/L)
0.15 ± 0.05 0.29 ± 0.11d 0.21 ± 0.04d 0.19 ± 0.02 0.37 ± 0.08e 0.57 ± 0.09e
Glc (mmol/L) 4.93 ± 0.58 5.98 ± 0.88d 3.94 ± 0.56d 4.37 ± 0.35 3.96 ± 0.88 3.63 ± 0.83d
LDH (U/L) 1241.62 ± 244.45 791.42 ± 189.04d 1468.97 ± 67.72 1464.27 ± 80.92 1210.10 ± 181.58d 526.71 ± 79.73e
BUN (mmol/L) 3.82 ± 1.56 6.26 ± 0.88d 14.09 ± 3.67e 5.80 ± 1.08 5.05 ± 0.68 4.62 ± 1.01d
Cn (µmol/L) 34.20 ± 3.56 47.00 ± 3.35e 54.67 ± 10.46d 57.14 ± 3.63 54.44 ± 2.74 50.11 ± 1.62e
BUN/Cn 0.10 ± 0.02 0.13 ± 0.01e 0.26 ± 0.04e 0.10 ± 0.01 0.09 ± 0.01 0.09 ± 0.02
UA (µmol/L) 141.00 ± 58.89 165.33 ± 43.89 143.83 ± 15.65 135.43 ± 34.67 172.00 ± 39.96 186.00 ± 38.81d
TBA (µmol/L) 33.60 ± 19.64 21.00 ± 8.19 22.42 ± 4.41 34.67 ± 14.30 21.94 ± 10.53 18.98 ± 5.38d
a C, control group; L, low-dose group; H, high-dose group; 6, 6 h post-dose; 48, 48 h post-dose.
b TP, total protein; Alb, albumin; Glo, globulin; Ibil, indirect bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
GGT, gamma glutamyltransferase; ALP, alkaline phosphatase; TG, triglycerides; TC, total cholesterol; HDL, high-density lipoprotein, LDL,
low-density lipoprotein; Glc, glucose; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; Cn, creatinine; UA, uric acid; TBA, total bile
acid.
c Each data value represents the mean ± SD.
d Significant differences between two groups as judged by Student’s t-test using SPSS with P < 0.05.
e Significant differences between two groups as judged by Student’s t-test using SPSS with P < 0.001.
Figure 3. Effect of MnO nanoparticle administration on
biodistribution of Mn. C, control group; L, low-dose group; H,
high-dose group; 6, 6 h post-dose; 48, 48 h post-dose; 20×,
multiplied 20-fold. ∗ Significant differences between two groups as
judged by Student’s t-test (∗P < 0.05; ∗∗P < 0.001).
together with the histological results suggests that liver, not
kidney, was the main organ for disposal and clearance of
Mn-NPs from the circulation.
3.4. Effect of Mn-NPs on serum biochemical parameters
Hepatocytes are responsible for synthesis of most of the
serum proteins, so serum proteins, including total protein
(TP), albumin (Alb), globulin (Glo), and albumin to globulin
ratio (Alb/Glo), were determined to evaluate liver function.
Table 1 shows a mild increase in TP, Alb, and Glo levels in the
low-dose group at 6 h pd. However, a slight reduction of Alb
and a mild rise of Glo resulted in a significant decrease (P <
0.001) in Alb/Glo ratio in both low- and high-dose groups
at 48 h pd (table 1). It is probable that Mn-NPs bound to
carrier proteins such as Alb, Glo, or even apolipoprotein and
induced upregulation of these carrier proteins as a protective
response [14].
γ -glutamyl transpeptidase (GGT), primarily present
in microsomal membranes of biliary epithelium, plays a
key role in glutathione (GSH) metabolism and xenobiotic
detoxification. Elevated serum GGT activity commonly
indicates bile duct or liver disease. Another sensitive
biochemical marker is alkaline phosphatase (ALP) to detect
obstructive biliary disease. Table 1 shows that GGT activities
in low- and high-dose groups were sharply increased by
25.0- and 45.9-fold at 6 h pd and 8.0- and 43.8-fold at
48 h pd, respectively, while ALP elevations were moderate,
to 152% (P < 0.001, low-dose group) and 140% (P <
0.05, high-dose group) at 6 h pd, and returned nearly to
control level 48 h pd (table 1). It is reasonable to assume
that Mn-NP-induced hepatocellular jaundice led to moderate
elevation in ALP activity and partially contributed to the
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elevation of GGT activity in serum, and Mn-NP-induced
oxidative stress possibly further increased the activity of GGT.
The activities of ALT and AST increased to 188%
(P < 0.001) and 183% (P < 0.001) in the low-dose group
and to 356% (P < 0.001) and 429% (P < 0.001) in the
high-dose group 6 h pd, respectively, and both enzyme
activities recovered nearly to the normal level at 48 h pd. The
ratios of AST/ALT in both the low- and high-dose groups
show significant decrease (P < 0.05) at 48 h pd. Clinically,
the change of their ratio can serve as an indication of liver
injury, in which a decrease implies mild hepatic injury and
an increase implies severe hepatic injury. Our results suggest
that the Mn-NP exposure had a slight effect on the normal
liver function at 48 h pd.
The concentrations of total cholesterol (TC) and HDL-C
in both Mn-NP-treated groups were increased at both 6 h
and 48 h pd (table 1). Similarly, the levels of LDL-C were
severely elevated. The triglyceride (TG) level moderately
increased at 6 h pd, but mildly decreased at 48 h pd (table 1).
In addition, the mean level of total bile acid (TBA) in all
Mn-NP-treated groups was decreased moderately, while only
in the high-dose group it was statistically significant at 48 h
pd. The liver plays a central role in cholesterol metabolism.
Cholesterol, from the diet or from de novo synthesis, is not
only secreted by hepatocytes for exporting to other cells, but
also converted to bile acids via cytochrome P450-mediated
oxidation and secreted into the intestine. The in vitro studies
have shown that substitution of heme iron with Mn inhibits
the enzyme activity of cytochrome P450 [15]. Therefore, we
assume that Mn ion release of Mn-NPs substituted the heme
iron of cytochrome P450 and reduced the efficiency of bile
synthesis and secretion. Furthermore, it has been confirmed
that the elevation of bilirubin level (table 1) and excess Mn
ions induced intrahepatic cholestasis, which caused further
reduction of bile salt secretion [16]. The inability of liver to
convert cholesterol from LDL and HDL into bile salts led to
the increased level of TC, HDL-C and LDL-C in serum. The
decrease of bile secretion affected the ensuing digestion and
absorption of fats and bile salts in the small intestine, which
directly led to the significant decrease of TG and TBA levels
at 48 h pd (table 1).
As shown in table 1, exposure of rats to Mn-NPs resulted
in an increase of creatinine (Cn) to 137% (P < 0.001) and
160% (P < 0.05), and the blood urea nitrogen (BUN) level
was severely increased to 164% (P < 0.05) and 369% (P <
0.001), while the corresponding ratio of BUN/Cn rose to
130% (P < 0.001) and 260% (P < 0.001) of control in
low- and high-dose groups at 6 h pd, respectively. At 48 h
pd, no apparent change was measured in the levels of Cn,
BUN and uric acid (UA) and the ratio of BUN/Cn between
the low-dose group and the control, while the results of
the high-dose group showed a decreased level of Cn (88%,
P < 0.001) and BUN (80%, P < 0.05), and an increased
level of UA (137%, P < 0.001). Cn is generated in muscle
with a fairly constant rate, and is filtered out of the blood
by the kidney. The histological results showed no obvious
change in renal structure upon Mn-NP treatment. Therefore,
we think that, beyond glomerular filtration capacity, both
hemolysis of red blood induced by Mn-NPs and electrolyte
disturbance/imbalance caused by the ion release of Mn-NPs
contributed to the elevation of Cn, BUN, and the ratio
of BUN/Cn at 6 h pd, while the concurrent actions from
hemolytic anemia and hypohepatia caused the decreased
levels of Cn and BUN in the high-dose group at 48 h pd.
3.5. 1H NMR profiles of biological fluids and tissues from
rats
Representative 1H NMR spectra of biological fluids (plasma
and urine) and tissue extracts (brain, lung, kidney, spleen and
liver) are shown in figure 4. The primary peaks in the spectra
were assigned to individual metabolites (table S1 in the
supplementary materials available at stacks.iop.org/Nano/24/
455102/mmedia) according to previous studies [13, 17], and
confirmed by a public NMR database (Human Metabolome
Database V3.0, see www.hmdb.ca) and an in-house developed
NMR database.
To get the overall metabolic information and examine
the intrinsic variation within the respective biocompartment,
unsupervised PCA was performed on the respective NMR
data sets. In the representative score plots (shown in figure 5),
the value of R2X in the lower left corner of plots represents
the explainable variance and the value of Q2 in the lower
right corner of plots is a measure of the predictive power
of the model in each panel. PCA results reveal that the
clusters of plasma and the extracts of kidney, liver, and
spleen from Mn-NP-treated groups were distinct from those
of the corresponding controls, which implies an obvious
change in the metabolic profiles induced by Mn-NPs, while
the samples of urine and the extracts of brain and lung
display some degree of overlap between the controls and
the corresponding dosed groups, which suggests a moderate
effect induced by Mn-NPs on these biological compartments.
Additionally, urinary metabonomic recovery in the high-dose
group could be observed to a certain degree, though not
complete, which offers some clues to the biochemical
processing of Mn-NPs in the body. The supervised OPLS-DA
model was then used to identify the metabolic difference
between the groups. The OPLS-DA score plots (left panels in
figures 6 and S3 available at stacks.iop.org/Nano/24/455102/
mmedia) give a clear separation between Mn-NP-treated
groups and the corresponding controls, and the OPLS-DA
loading plots (middle and right panels in figures 6 and
S3 available at stacks.iop.org/Nano/24/455102/mmedia) offer
an insight into the types of metabolite responsible for the
separation, based on the first principal component. The
significant class-discriminating metabolites corresponding to
all pairwise groups are tabulated in tables 2, 3(A) and (B),
and S2 (available at stacks.iop.org/Nano/24/455102/mmedia),
and provide the biochemical alterations in the different
biocompartments following the administration of Mn-NPs.
3.5.1. Metabonomic analysis of plasma. According to
OPLS-DA analysis of NMR data from plasma (table 2),
the levels of 1-methylhistidine, VLDL, –CH2–CH2–C=O
(L5), allantoin, leucine (Leu), threonine (Thr), glycerophos-
phocholine (GPC), pyruvate, glutamine (Gln), choline,
6
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Figure 4. Typical 1H NMR spectra of plasma, urine and aqueous brain, lung, kidney, spleen and liver extracts from a low-dosed rat at 6 h
pd. The region of δ 6.5–9.5 (in the dashed box) in the spectrum was magnified 16-, two- or tenfold in vertical expansion compared with the
corresponding region of δ 0.5–6.4. AA, acetoacetate; Ace, acetate; Act, acetone; AD, acetamide; Ade, adenosine;
AH, aminohippurate; Ala, alanine; All, allantoin; AMP, adenosine monophosphate; Asp, aspartate; Ben, benzoate; Bet, betaine;
Bu, butyrate; Ch, choline; Ci, citrate; CL, cholate; Cn, creatinine; Cr, creatine; Cyt, cytidine; DG, deoxyguanosine; DMA, dimethylamine;
DMG, N,N-dimethylglycine; EA, ethanolamine; Eth, ethanol; For, formate; Fum, fumarate; G, glycerol; GA, guanidinoacetate;
GABA, gamma-aminobutyrate; Glg, glycogen; α-Glc, alpha-glucose; β-Glc, beta-glucose; Gln, glutamine; Glu, glutamate; Gly, glycine;
GPC, glycerophosphocholine; GSH, glutathione; Gu, guanosine; 2-HB, 2-hydroxybutyrate; 3-HB, 3-hydroxybutyrate; HG, homogentisate;
HIB, 2-hydroxyisobutyrate; Hip, hippurate; His, histidine; p-HPA, para-hydroxyphenylacetate; HX, hypoxanthine; m-I, myo-inositol;
IB, isobutyrate; Ile, isoleucine; Ino, inosine; KG, alpha-ketoglutarate; L1, LDL, CH3 –(CH2)n–; L2, VLDL, CH3 –(CH2)n–; L3, LDL,
CH3– (CH2)n–; L4, VLDL, CH3– (CH2)n–; L5, VLDL, –CH2 –CH2–C=O; L6, lipid, –CH2 –CH=CH–; L7, lipid, –CH2 –CH2–CH=CH–;
L8, lipid, –CH2–C=O; L9, lipid =CH–CH2–CH=; L10, lipid, –CH=CH–; Lac, lactate; Leu, leucine; Lys, lysine; MA, methylamine;
Met, methionine; MG, methylguanidine; MH, 1-methylhistidine; 3-MH, 3-methylhistidine; MM, methylmalonate; MN,
1-methylnicotinamide; Mol, methanol; N, nicotinate; NA, nicotinamide; NAA, N-acetylaspartate; NAD, NAD+; NADP, NADP+; NAG,
N-acetylglutamate; NAS, N-acetylglycoprotein signals; OA, oxaloacetate; OAS, O-acetylglycoprotein signals; OIV, 2-oxoisovalerate; Oro,
orotate; PAG, phenylacetylglycine; Pan, pantothenate; PC, phosphocholine; PEA, phosphoethanolamine; PG, pyroglutamate; Phe,
phenylalanine; Prop, propionate; Py, pyruvate; Sar, sarcosine; Ser, serine; Suc, succinate; Tau, taurine; Thr, threonine; TMAO,
trimethylamine N-oxide; tri, trigonelline; Trp, tryptophan; Tyr, tyrosine; Uc, urocanate; Ud, uridine; U-Glc, uridine diphosphate glucose;
Ura, uracil; Val, valine; Xan, xanthine.
citrate, and phenylalanine (Phe) were changed only in
the high-dose group at 6 h pd, while lipid –CH2–C=O
(L8), tyrosine (Tyr), and lactate were changed in all
groups except the low-dose group at 48 h pd. In con-
trast, the levels of isobutyrate, LDL CH3–(CH2)n–(L1),
VLDL CH3–(CH2)n–(L2), LDL CH3–(CH2)n–(L3), lipid
–CH2–CH=CH–(L7), lipid –CH=CH– (L10), alanine (Ala),
methionine (Met), lysine (Lys), glycerol, myo-inositol, lipid
–CH2–CH2–CH=CH– (L6), O-acetylglycoprotein, serine
(Ser), creatine, glycine (Gly), formate, and isoleucine (Ile)
exhibited a time-dependent response. However, the levels of
N-acetylglycoprotein, betaine, lipid =CH–CH2–CH= (L9),
acetone, acetate, and glucose were changed in a complicated
manner.
Consistent with blood biochemical analysis (table 1), the
elevated lipid levels in the plasma samples at 6 h pd were
followed by a drop. We hypothesize that Mn-NP exposure
depleted the main substrates of oxidative phosphorylation,
namely oxygen and glucose, during the period of acute
response, and induced a metabolic switch from glucose to
fatty acid oxidation, which stimulated lipolysis and fatty acid
release into the bloodstream, and finally resulted in a rise of
fatty acids, triglycerides, lipoproteins, and ketone bodies such
as acetone (figure 6 and table 2).
Choline, sarcosine, dimethylamine, Met, formate, and
betaine are the sources of methyl groups. The methylation
process helps the body to respond to stress, to detoxify
xenobiotics, and to create new cells. Methyl deficiency, as
reflected in low levels of those metabolites with methyl
sources such as choline, Met, formate, and betaine at different
time points (table 2), suggests that methylation played an
important role in the detoxification of Mn-NP exposure.
Similar results were also observed in the corresponding
splenic, hepatic, and urinary metabonomes (tables 3(A) and
(B)).
1-methylhistidine is derived from anserine via the
hydrolysis of carnosinase. Previous studies showed that Mn2+
ions increased the activity of carnosinase [18]. The increased
level of 1-methylhistidine (table 2) may be a natural outcome
of the activated carnosinase. Besides, its elevation may also be
a stimulating action to hemopoietic function for compensating
the decrease in the number of erythrocytes from the hemolysis
7
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Figure 5. Representative PCA score plots (PC1 versus PC2) derived from the 1H NMR data of body fluid samples (plasma and urine) and
tissue samples (extracted from brain, kidney, liver, lung, and spleen) from the corresponding groups of rats: C, control group; L, low-dose
group; H, high-dose group; 0, 0 h post-dose; 6, 6 h post-dose; 24, 24 h post-dose; 48, 48 h post-dose.
induced by nanoparticle exposure. In addition, allantoin is
the end-product of purine metabolism in rats. The reduction
of allantoin in the brain and liver and the increase in blood
and urine (figure 6, table 2) suggest that Mn-NPs promoted
both the secretion of allantoin from tissues and the excretion
through the kidneys.
3.5.2. Metabonomic analysis of urine. The body’s
metabolites are exchanged between blood and organs and
then transported into the kidneys, where metabolic wastes
are finally excreted into the urine. Thus urine formation is a
time-consuming process. Analysis of the urinary metabolites
(figure 6, table 2) may provide the time- and dose-response
information that can be used to determine the onset and sever-
ity of toxicity [9]. The changes in metabolite concentrations
at 6 h pd seemed to be linked to the early effects of Mn-NPs
on the kidney and circulatory system, displayed in the concen-
tration variations of N-phenylacetylglycine, citrate, allantoin,
methylmalonate, creatine, formate, xanthine, acetamide, 1-
methylnicotinamide, acetone, 2-oxoisovalerate, and succinate,
while the changes at 48 h pd could reflect the metabolic
alterations in the other organs upon Mn-NP exposure, which
included the concentration variations of nicotinate, lactate,
hippurate, betaine, 4-hydroxyphenylacetate, methylamine,
Ala, and Gly. The alterations in the contents of Cn, urocanate,
and guanidinoacetate showed a dose-dependent response,
while some other metabolites demonstrated a complicated
effect of time and dose responses.
Niacin, also known as vitamin B3, inhibits the release
of free fatty acids from the adipocytes. A decrease in
urinary excretion of niacin and its metabolites trigonelline
and nicotinamide N-oxide may mean that more niacin and its
metabolites were kept in the body to cope with the high serum
lipid levels that have been observed in serum biochemical
analysis. In addition, MNA has been proven to be an
antithrombotic, which regulated thrombotic and inflammatory
processes in the cardiovascular system by a mechanism
involving cyclooxygenase-2 and prostacyclin [19]. The
increased level of MNA in the urine suggests that high-dose
Mn-NP exposure possibly caused thrombosis or inflammation
in the circulatory system.
Usually, elevated Cn levels in urine are a sign of impaired
kidney function, while in this case we suppose the increases of
urinary creatine and Cn excretion in the high-dose group were
due to the increased protein catabolism. This is consistent with
the conclusion drawn from the serum biochemical analysis.
Guanidinoacetate is synthesized from arginine and Gly, and
consumes a methyl group to form creatine. In addition, as the
product in histidine catabolism and the substrate of urocanase,
the decreased level of urocanate in the high-dose group may
reflect the activation of urocanase by Mn2+ [20].
The detoxification process for the toxic effect induced
by Mn-NPs caused a vitamin B12 deficiency, which made
it unavailable to catalyze conversion of methylmalonate into
succinate, and thus led to a high methylmalonate level and a
low succinate present in urine. Mn is an essential co-factor for
xanthine oxidase, and Mn-NPs stimulated this enzyme, which
converts xanthine to UA, and subsequently to allantoin. This
may be the reason for the diminished excretion of xanthine
and the elevated excretion of allantoin.
N-phenylacetylglycine (PAG) is a putative biomarker of
phospholipidosis, and the elevation of urinary PAG indicated
the impact of Mn-NP exposure on phospholipid metabolism.
In addition, consistent with the plasma NMR data, low
urinary citrate and alpha-ketoglutarate excretion suggest that
Mn-NP exposure caused a switch from aerobic to anaerobic
respiration and induced the alteration of Ala, ethanol, and
8
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Figure 6. Representative OPLS-DA score plots (left panel) derived from the 1H NMR data of body fluid samples (plasma and urine) and
tissue samples (extracted from brain, kidney, liver, lung, and spleen) and corresponding coefficient loading plots (middle and right panels)
obtained from different pairwise groups. C, control group; L, low-dose group; H, high-dose group; 6, 6 h post-dose; 24, 24 h post-dose; 48,
48 h post-dose. Q2 indicates the predictability of the model, and R2X represents the total explainable variation. The color code corresponds
to the correlation coefficients of the metabolic variables. The loading plots identifying discriminatory metabolites between pairwise classes
are based on the first principal component (t[1]P). Signals with a positive direction relate to the abundance of metabolites in the groups in
the positive direction of t[1]P, and vice versa. Keys for the assignments are shown in the notes of figure 2 and the detailed information is
listed in tables 2, 3, S2, and S3 (available at stacks.iop.org/Nano/24/455102/mmedia).
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Table 2. Summary of metabolic variations in rat body fluids induced by Mn-NPs between different pairwise groups.
Plasma Urine
Metabolites C6–L6 C6–H6 C48–L48 C48–H48 Metabolites C6–L6 C6–H6 C24–L24 C24–H24 C48–L48 C48–H48
MHa — 0.85 — — MN — 0.76 — — — —
L5 — 0.93 — — Act — 0.85 — — — —
All — 0.87 — — OIV — 0.89 — — — —
Leu — 0.84 — — Suc — −0.92 — — — —
Thr — 0.80 — — AD — −0.89 — −0.88 — —
GPC — −0.91 — — Cr — 0.76 — 0.98 — —
Py — −0.93 — — For — −0.92 — −0.88 — —
Gln — −0.78 — — MM — 0.91 — 0.82 — —
Ch — −0.76 — — Xan — −0.89 — −0.79 — —
Ci — −0.94 — — All 0.87 0.77 — 0.82 — 0.89
Phe 0.81 0.95 — 0.77 PAG 0.75 0.89 0.86 0.94 — 0.80
L8 0.79 0.93 — 0.91 Ci −0.83 −0.95 −0.89 −0.98 — −0.90
Tyr −0.89 −0.88 — −0.78 Ala — — — −0.87 — —
Lac −0.81 0.92 — −0.80 Gly — — — −0.80 — —
IB 0.94 0.77 — — MA — — — −0.88 — —
L1 0.95 0.79 — — p-HPA — — −0.81 −0.86 — —
L2 0.90 0.75 — — Bet — — −0.78 −0.75 — −0.81
L3 0.89 0.91 — — Hip — — −0.78 −0.93 — −0.95
L7 0.89 0.88 — — Lac — — −0.81 −0.88 — −0.85
L10 0.90 0.86 — — N — — −0.86 −0.95 −0.92 −0.91
Ala −0.96 −0.96 — — Cn — 0.77 — 0.85 — 0.81
Met −0.76 −0.83 — — Uc — −0.76 — −0.91 — −0.77
Lys −0.90 −0.86 0.75 0.78 GA — — 0.81 — 0.79 —
G — — 0.95 0.91 Ch 0.84 — — — — —
m-I — — 0.93 0.92 KG −0.87 −0.98 — — — —
L6 — — 0.92 0.91 AA — — 0.81 0.87 — —
OAS — — 0.96 0.93 2-HB — — 0.81 — — —
Ser — — — 0.88 Tau — — — — — −0.87
Cr — — — 0.79 NAS — −0.96 −0.84 −0.94 — −0.88
Gly — — — 0.85 Tri — −0.96 −0.87 −0.97 — −0.82
For — — — −0.78 Eth — 0.83 — −0.92 — —
Ile — — −0.80 — Py — −0.88 0.79 0.80 — 0.83
NAS 0.88 — 0.94 0.97 Sar — — −0.90 −0.91 −0.88 0.77
Bet −0.94 — −0.80 −0.83
L9 0.94 0.90 −0.81 —
Act — 0.95 −0.75 —
Ace — −0.76 0.82 —
α-Glc — −0.94 0.83 —
β-Glc — −0.93 0.80 —
a Abbreviations in tables explained in the notes of figure 2.
pyruvate. The high level of ketone bodies including acetone
and acetoacetate in the urine of the dosed group also suggests
that fatty acids were used as an alternative source of energy.
3.5.3. Metabonomic analysis of liver. As identified by the
biodistribution results (figure 3), liver was a Mn-NP-targeted
organ. Therefore, most of the endogenous metabolites in
the liver changed upon Mn-NP treatment, as shown in
table 3(A). Among them, the concentration changes of
Ala, AMP, Tyr, dimethylamine, valine (Val), tryptophan
(Trp), fumarate, 3-hydroxybutyrate, adenosine, niacinamide,
trigonelline, 2-hydroxyisobutyrate, Phe, N-acetylglutamate
(NAG), choline, Ile, GPC, GSH, phosphocholine (PC),
allantoin, glycogen, oxaloacetate, glutamate (Glu), and
glucose were directly correlated with Mn content. The
changes of Leu, aspartate (Asp), γ -aminobutyrate (GABA),
and guanosine were high-dose specific, while that of formate
and propionate were low-dose specific. Pyroglutamate,
betaine, acetate, lactate, Gln, uridine, Gly, uracil, succinate,
NAD+, and NADP+ demonstrated a complicated effect of
body response to Mn-NP exposure.
The elevation of aromatic amino acids including Trp,
Tyr, and Phe has been proposed for predicting the extent
of hepatic necrosis and possibly outcome [21]. The obvious
increase of Trp, Tyr, and Phe in our study implies that
high-dose Mn-NP exposure induced to a certain extent hepatic
or splenic necrosis at 6 h pd. As a natural biological response,
a detoxification process was stimulated; correspondingly,
NAD(P), FADH2, and their substrate niacinamide were
elevated in the liver. Consistent with this result, the excretion
of urinary niacin, niacinamide, and their metabolites was
decreased. In addition, we noticed the levels of branched-
chain amino acids (BCAAs) including Val, Leu, and Ile,
as important nutrients in the detoxification process, were
strongly correlated to tissue distribution of Mn-NPs in brain,
liver, and spleen (table 3(A)).
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Table 3. Summary of metabolic variations in (A) liver extracts induced by Mn-NPs between different pairwise groups and (B) rat tissues
induced by Mn-NPs between different pairwise groups.
(A)
Metabolites C6–L6 C6–H6 C48–L48 C48–H48 Metabolites C6–L6 C6–H6 C48–L48 C48–H48
Alaa — 0.85 — — OA 0.89 0.86 0.80 0.76
AMP — 0.98 — — Glu 0.88 0.91 0.77 0.88
Tyr — 0.92 — — β-Glc −0.91 −0.98 −0.91 −0.86
DMA 0.82 0.85 — — α-Glc −0.97 −0.99 −0.87 −0.92
Val 0.91 0.98 — — Leu — 0.81 — 0.77
Trp 0.91 0.88 — — Asp — 0.82 — 0.87
Fum 0.91 0.87 — — GABA — 0.79 — 0.76
3-HB 0.88 0.82 — — Gu — 0.85 — 0.88
Ade 0.85 0.88 — — For 0.97 — 0.90 —
NA 0.99 0.95 — — Prop 0.84 — 0.88 —
Tri 0.84 0.80 — — Bet −0.76 — — —
2-HIB −0.77 −0.79 — — Ace — — 0.80 —
Phe 0.97 0.99 — 0.80 Lac — — — 0.78
NAG 0.92 0.95 — 0.80 Gln — — — 0.90
Ch 0.89 0.94 — 0.83 Ud — — — −0.80
Ile 0.85 0.88 — 0.76 Gly — — — −0.75
GPC 0.82 0.95 — 0.86 Ura 0.82 0.89 −0.79 —
GSH 0.91 0.94 — 0.78 Suc — 0.93 0.76 —
PC 0.78 0.88 — 0.82 PG 0.96 0.88 0.89 —
All −0.94 −0.92 — −0.88 NAD −0.91 — −0.91 0.92
Glg −0.98 −0.98 — −0.92 NADP −0.89 — −0.95 0.82
(B)
Brain Spleen
Metabolites C6–L6 C6–H6 C48–L48 C48–H48 Metabolites C6–L6 C6–H6 C48–L48 C48–H48
Gu — −0.82 — — Tyr — 0.84 — —
Phe 0.79 0.91 — 0.75 Lac — 0.95 — —
GABA 0.93 0.96 0.79 0.76 Ile 0.86 0.78 — —
m-I 0.99 0.97 0.84 0.83 Val 0.83 0.81 — 0.82
Ura 0.83 0.88 0.87 0.87 Phe 0.92 0.96 — 0.85
Prop −0.85 −0.85 0.85 −0.93 Suc 0.78 0.78 0.88 0.88
Lac 0.99 0.99 — — Bet — — −0.94 −0.95
Cr 0.99 0.98 — — Ala — — — 0.82
Glu 0.98 0.97 — — EA — — — 0.83
Cyt 0.85 0.77 — — m-I — — — 0.88
Ade 0.89 0.79 — — NAD — — — 0.95
Asp 0.81 0.88 — — Tau — — — −0.75
β-Glc −0.94 −0.92 — — PC — — — −0.93
PEA −0.84 −0.79 — — Ace — — 0.78 —
All −0.95 −0.95 — — Cn — — 0.92 —
Tau −0.85 −0.87 — — For — — 0.93 —
PC −0.88 −0.76 — — α-Glc — — −0.79 —
α-Glc −0.93 −0.93 — — Sar — — −0.71 —
Glg −0.92 −0.93 — — Lys 0.80 — — —
Val −0.83 −0.81 — — DMG 0.83 — — —
GPC −0.84 −0.86 — — Leu 0.85 — — —
Thr −0.93 −0.91 — — Glu 0.91 — — —
For 0.94 — 0.93 — Prop — — 0.92 −0.78
Cn 0.97 — 0.94 — PG — −0.75 0.94 —
Eth −0.79 −0.75 −0.84 — NA — 0.77 0.88 —
NAD −0.91 −0.84 −0.76 — Cr −0.78 — 0.77 0.83
NAA 1.00 0.99 0.76 — Ura 0.77 0.78 −0.76 —
Suc 0.75 — — —
Fum 0.84 — — —
Ile −0.81 — — —
Ace — — — −0.75
PG 0.99 — 0.88 −0.95
Leu −0.85 −0.84 — 0.80
a Abbreviations in tables explained in the notes of figure 2.
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GSH is synthesized and metabolized via the γ -glutamyl
cycle. The elevated GSH levels in liver were associated with
the formation of reactive metabolite in response to Mn-NP
exposure. As an intermediate in the γ -glutamyl cycle, the
high level of pyroglutamate in brain, liver, lung, and spleen
tissues suggests that more GSH was needed for detoxification.
Besides, when cystathionine is converted to cysteine and
incorporated into GSH, 2-hydroxybutyrate is released and
excreted into urine (table 2).
Urea production occurs primarily in the liver. Carbamoyl
phosphate synthetase I is essential for urea synthesis, while its
activity is absolutely dependent on NAG, which is synthesized
from acetyl-CoA and Glu. Our results show that the variation
of NAG content was correlated with Mn content in the liver.
This suggests that Mn-NPs promoted amino acid catabolism.
Besides, the alternation of fumarate, oxaloacetate, Gln, Glu,
and Asp levels may also be related to the nitrogen metabolism.
Catabolism of putrescine, one of the polyamines, occurs
along different pathways, but GABA is as a common
intermediate. S-adenosylmethionine is the principal methyl
donor and precursor for polyamines. Though the function of
polyamines is not entirely clear, they play an essential role
in promoting cell growth and hepatic regeneration. Thus an
increase of GABA concentration in high-dose groups could
imply the regeneration of hepatic injury induced by Mn-NP
administration.
Choline-like metabolites such as choline, PC, and
GPC take part in several important biochemical pathways,
including a signaling and structural role for cell membranes
and an immune response regulator. Previous studies have
shown that PC bound to C-reactive protein, subsequently acti-
vated complement, and began the phagocytotic immunologic
response [22]. So it is possible that elevated levels of these
metabolites help to remove the damaged liver cells.
3.5.4. Metabonomic analysis of brain. In brain ho-
mogenates, guanosine, Phe, GABA, myo-inositol, uracil,
and propionate may be related to the Mn content in
the brain. The levels of lactate, creatine, Glu, cytidine,
adenosine, Asp, glucose, O-phosphoethanolamine, allantoin,
taurine, PC, glycogen, Val, GPC, and Thr were changed
in a time-dependent manner (table 3(B)). The alteration
of formate and Cn were specific in the low-dose group.
However, the succinate, fumarate, Ile, acetate, ethanol,
NAD+, and N-acetylaspartate (NAA) levels were changed in
a complicated manner.
Three intermediates of the GABA shunt (in which
the inhibitory neurotransmitter GABA is synthesized and
degraded), GABA, Glu, and succinate, were increased in
brain tissue at 6 h pd. Previous studies revealed that Mn
exposure inhibited the synthesis and release of glutamine [23].
Moreover, creatine and Cn served as indicators of brain energy
metabolism in depression [24]. Whether the increased level of
these metabolites caused mental depression in rats is unclear.
However, Mn-NP exposure influenced neurotransmission,
which might affect the brain energy metabolism in rats.
Consistent with the result of plasma, Mn-NP exposure
caused an increase in the oxygen consumption, and stimulated
anaerobic glycolysis, which may be responsible for the
increased level of lactate and the decreased levels of glucose
and glycogen in brain, lung, and spleen samples (table 3(B)).
Under anaerobic conditions, formate, acetate, fumarate, and
succinate were produced and in the presence of citrate with
the reaction: 2 lactate+1 citrate → 3 acetate+2 formate+1
fumarate (the ensuing reduction of fumarate to succinate).
Lactate is further reduced to propionate, and acetyl-CoA can
be reduced to ethanol. In addition, as an important fuel source,
the levels of BCAAs were decreased with increased energy
consumption at 6 h pd. This conclusion was supported by
the increased urinary 2-oxoisovalerate (an intermediate in the
BCAA catabolic pathway). In addition, NAA is synthesized
in the mitochondria of neurons from Asp and acetyl-CoA.
One possible physiological role for NAA is in adjusting the
intracellular osmolarity, together with myo-inositol, GPC, and
taurine.
A comprehensive difference in metabolic profiles was
also observed with time in the control groups (data
not shown), which included an increase of GABA,
lactate, creatine, Glu, Cn, and NAA and a decrease of
O-phosphoethanolamine, allantoin, taurine, PC, glucose,
glycogen, Val, GPC, Thr, NAD+, and Leu at 48 h pd.
Previous studies have shown that the stress of normal
intravenous injection caused release of stress hormones in a
time-dependent manner. Although there is no evidence that
the restraint stress can affect the Mn ion distribution, the
toxic effects of Mn-NPs may be more obvious in a stressful
situation [25]. We assume that the restraint stress would
enhance the neurotoxic effects of Mn-NP exposure on global
metabolite profiles; however, these effects on the brain could
be transient and recoverable (figure 3 and table 3(B)).
3.5.5. Metabonomic analysis of spleen. In spleen
homogenates, the alterations of Tyr, lactate, Ile, Val, Phe,
and succinate were dependent on Mn biodistribution in the
spleen, while the change of betaine was time dependent. The
other metabolites, such as Ala, ethanolamine, myo-inositol,
NAD+, taurine, PC, acetate, Cn, formate, glucose, sarcosine,
Lys, dimethylamine, Leu, Glu, propionate, pyroglutamate,
niacinamide, creatine, and uracil were changed in a
complicated manner (table 3(B)).
Previous evidence has shown that excessive Mn inhibited
the activity of succinic dehydrogenase [26], which led to
increased succinate levels in spleen. PC and ethanolamine are
components for the synthesis of phospholipids. Myo-inositol
is a secondary messenger in the PI3K/Akt signaling pathway
and an intracellular organic osmolyte. Taurine is involved
in many physiological processes, including osmoregulation,
toxic intermediate clearance, and calcium mobilization [27].
Ala is one of the most abundant amino acids in the body,
it can be easily synthesized from pyruvate and BCAAs, and
it is extensively used as an intermediate in many metabolic
pathways such as glycolysis, gluconeogenesis, tricarboxylic
acid cycle, and Ala cycle. High niacinamide could help the
spleen detoxify Mn-NPs, which also took place in the liver,
lung, and kidney. Creatine is naturally produced in the body
from amino acids and dehydrated to form the cyclic shift base
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Cn in rat heart, spleen, and skeletal muscle and excreted by
kidney. Relatively speaking, among all observed tissues, the
metabolic profile of spleen was less affected by Mn-NPs.
3.5.6. Metabonomic analysis of kidney and lung. Mn-NPs
induced weaker effects on kidney and lung, and metabolic
variations seem to be closely correlated with the blood
clearance and the biodistribution of Mn-NPs as identified by
ICP-AES (figure 3). Time-dependent changes were observed
in the levels of betaine, uracil, myo-inositol, GPC, Glu,
Val, pantothenate, and Tyr in the renal metabonome, while
succinate, lactate, cytidine, Glu, uracil, glycogen, and glucose
were changed in a Mn content-dependent manner in the lung
metabonome (table S2 available at stacks.iop.org/Nano/24/
455102/mmedia). Betaine, myo-inositol, GPC, and Glu help
osmoregulate the extracellular osmolality, and the changes in
the levels of succinate, betaine, choline, and Glu seem to be
related to the detoxification process in response to Mn-NP
exposure [28]. As important intermediates of fatty acid,
protein, and RNA synthesis, the variations of pantothenate,
Phe, cytidine, uracil, Val, and Tyr implied the disturbance of
the related metabolic pathways induced by Mn-NP treatment.
According to our results, exposure to Mn-NPs had
effects on a number of metabolic pathways including energy,
lipid, amino acid, and other nutrient metabolism in rats.
Furthermore, the information of absorption, transportation,
biodistribution, and excretion could be derived from the
variations of the metabolites in the specific tissues. However,
the disturbance and impairments of biological functions
induced by nanoparticles are closely correlated with the
particle size and surface chemistry [13, 29]. Therefore, it is
feasible to improve their biocompatibility and safety profiles
by optimizing the particle size and modifying the surface
structure when Mn-NPs are used as MRI contrast agents.
4. Conclusions
Exposure to Mn-NPs could lead to disturbances of a
number of metabolic processes in the organism. However,
the detoxification system in vivo is so complex and
influenced by so many regulatory mechanisms that no
single technology can fulfil complete analyses. In this
study, we integrated the traditional biochemical analyses
with NMR-based metabonomics as a systematic approach
to investigate the toxicological effects of in vivo exposures
to Mn-NPs. The dysfunction induced by Mn-NPs was
demonstrated as variations of all kinds of metabolite in
specific tissues. The removal of nanoparticles from the body is
a biochemical process known as detoxification or metabolism.
As an important factor in ADME, the detoxification process
directly affects distribution and excretion. In addition, the
biocompatibility and safety profiles could be improved by
optimizing the particle size and modifying the surface
structure when Mn-NPs are used as MRI contrast agents. Our
results suggest that NMR-based metabonomic analysis is a
suitable approach for evaluating the ADME/Tox properties of
Mn-NPs in contrast agent development, which would provide
identifiable ground for candidate selection and optimization.
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